Mechanism of antagonism of thromboxane receptors in vascular smooth muscle

1987 ◽  
Vol 133 (1) ◽  
pp. 89-96 ◽  
Author(s):  
Atsuo Yanagisawa ◽  
James A. Smith ◽  
Mark E. Brezinski ◽  
Allan M. Lefer
1992 ◽  
Vol 262 (4) ◽  
pp. C927-C933 ◽  
Author(s):  
G. W. Dorn ◽  
M. W. Becker

Growth factors, in addition to being mitogenic, may modulate vascular smooth muscle differentiation. We tested whether serum or defined growth factors could regulate thromboxane A2 (TxA2) receptors in cultured rabbit aorta smooth muscle cells. Fetal bovine serum (10%) stimulated cell proliferation and DNA synthesis in subconfluent cell cultures. Binding of the thromboxane A2 agonist [1S-(1 alpha 2 beta(5Z),3 alpha(1E,3S),4 alpha)]-7-[3-(3-hydroxy-4-p- iodophenoxy-1-butenyl)-7-oxabicyclo[2.2.1]heptan-2-yl]-5-hep tenoic acid showed a 41% decrease in TxA2 receptors in cells treated with 10% serum compared with serum-deprived (0.1%) controls. Receptor downregulation by serum was gradually reversible upon serum withdrawal. Compared with serum-deprived cells, those exposed to 10% serum also had diminished TxA2-stimulated phosphatidylinositol hydrolysis. Regulatory actions of serum on TxA2 receptors were distinguished from mitogenic effects with heparin, which prevented cell growth but did not inhibit serum-induced downregulation of TxA2 receptors. Furthermore, low concentrations of platelet-derived growth factor and basic fibroblast growth factor decreased TxA2 receptors without stimulating cell proliferation or DNA synthesis. These observations describe a previously unrecognized regulatory action of growth factors on a vascular smooth muscle vasoconstrictor receptor, an action which is independent of effects on cell proliferation or DNA synthesis.


2016 ◽  
Vol 36 (suppl_1) ◽  
Author(s):  
Oula K Dagher ◽  
Miran A Jaffa ◽  
Aïda Habib ◽  
Fuad N Ziyadeh ◽  
Louis M Luttrell ◽  
...  

The development of an atherosclerotic lesion in an injured vasculature is highly dependent on the proliferative state of vascular smooth muscle cells (VSMC). Bradykinin (BK) and Thromboxane are two G-protein coupled receptor ligands, whose individual binding to their respective receptors, B 2 R and TP, promotes ERK1/2-mediated VSMC proliferation. However, it is not yet known whether receptor-receptor interactions between B 2 R and TP could contribute to their co-regulation. Thus, our work addresses the hypothesis that, in VSMC, B 2 R and TP form functional hetero-complexes, of distinct trafficking and signaling properties. B 2 R-TP signaling crosstalk was first analyzed in rat VSMC by Western Blot analysis and subsequent fold/basal quantification of ERK1/2 phosphorylation. B 2 R-TP cooperation was evident through the synergistic ERK1/2 phosphorylation, in VSMC co-stimulated with optimized combinations of BK and the TP agonist, IBOP (21.05 ± 4.93 fold of basal, n=3; p < 0.001). Interestingly, however, pretreatment with the TP antagonist, SQ29548, totally abolished (BK+IBOP)-induced ERK1/2 (n=3; p < 0.001). Furthermore, knowing that B 2 R, unlike the human TPα isoform, undergoes agonist-induced sequestration and β-arrestin2 recruitment, we conducted immunofluorescence analysis on HEK293T cells overexpressing human B 2 R and human TPα (B 2 R-TPα-HEKs). While stimulation with IBOP failed to mobilize cell membranous B 2 R or TPα, substantial co-internalization of TPα and B 2 R was seen, subsequent to stimulation of B 2 R-TPα-HEKs with BK. Likewise, overexpressing β-arrestin2 in B 2 R-TPα-HEKs resulted in co-localization of B 2 R, TPα, and β-arrestin2 within internalized puncta, only after BK stimulation. Pretreatment with SQ29548 inhibited BK-induced co-internalization and β-arrestin2 recruitment. However, SQ29548 could not reverse BK-induced B 2 R sequestration in HEK293T cells overexpressing B 2 R alone, thus excluding the possibility of direct SQ29548 - B 2 R binding. Finally, results of our ongoing work are the first to show nuclear localization of B 2 R and TP within human and rat VSMC. Thus, our findings favor the likelihood of functional B 2 R-TP heterodimerization in VSMC, which could serve as a novel target for interventional strategies.


Author(s):  
Martin Hagopian ◽  
Michael D. Gershon ◽  
Eladio A. Nunez

The ability of cardiac tissues to take up norepinephrine from an external medium is well known. Two mechanisms, called Uptake and Uptake respectively by Iversen have been differentiated. Uptake is a high affinity system associated with adrenergic neuronal elements. Uptake is a low affinity system, with a higher maximum rate than that of Uptake. Uptake has been associated with extraneuronal tissues such as cardiac muscle, fibroblasts or vascular smooth muscle. At low perfusion concentrations of norepinephrine most of the amine taken up by Uptake is metabolized. In order to study the localization of sites of norepinephrine storage following its uptake in the active bat heart, tritiated norepinephrine (2.5 mCi; 0.064 mg) was given intravenously to 2 bats. Monoamine oxidase had been inhibited with pheniprazine (10 mg/kg) one hour previously to decrease metabolism of norepinephrine.


Sign in / Sign up

Export Citation Format

Share Document